News

A discussion based on an FDA-cleared objective ADHD diagnostic test developed by Qbtech.

The rare genetic disease causes the body's immune system to not function properly.

A decision from the federal agency is expected in the fourth quarter of 2024.

With the approval comes the immediate availability of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses for patients between 2 to 5 years of age.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

New cohort analyses observe a statistically raised risk of myocarditis, pericarditis and seizures among certain age groups, though the data do not go against FDA recommendations.

Though concern exists about the associations of marijuana legalization and youth use, no links were found in a recent study.

Research in AJOG: Maternal hyperoxygenation doesn't boost neonatal Apgar scores in pathologic fetal heart rate tracing, showing no FiO2 benefit.

Study in JAMA: Antenatal corticosteroids don't impact neurodevelopment in late preterm children aged 6 years and up.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the April 2024 issue of Contemporary Pediatrics.

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

An assessment into development scores before, during and after the COVID-19 pandemic show children aged 0 - 5 years old may only had been minimally impacted in communication and problem-solving skills.

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A new study explored increased health care utilization of children among several specific sleep disorders, race, and age.

Cohort analysis shows the rate of RSV hospitalizations among children up to 5 years old skyrocketed in 2021—and then nearly doubled again in 2022—compared to pre-pandemic rates.

This analysis looked at the potential connection between SARS-CoV-2 test positivity and new asthma diagnoses.

A discussion of outpatient management and treatment of eating disorders in youth patients, plus the importance of a multidisciplinary team throughout the process.

A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.

A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.

A study recently published in Nature Mental Health found how social stress in adolescence can have long-lasting effects in female mice, with implications for postpartum depression (PPD) in humans.

The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.

“These findings suggest that primordial and primary interventions to prevent and reduce elevated childhood non–HDL-C levels may help prevent premature CVD," wrote the study authors.

The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.